Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: John Romeo who wrote (5497)	10/14/1998 1:48:00 PM
From: Joe E.	Read Replies (1) \| Respond to of 6136

This bit of bad news from the CDC prevention news sounds positive for Remune, and thus AGPH: "Lack of T-Cell Proliferative Response to HIV-1 Antigens After 1 Year of Highly Active Antiretroviral Therapy in Early HIV-1 Disease [Research Letter]" Lancet (10/10/98) Vol. 352, No. 9135, P. 1194; Plana, Montserrat; Garcia, Felipe; Gallart, Teresa A team of Spanish researchers investigated virus-specific CD4 T-cell helper responses in patients receiving highly active antiretroviral therapy (HAART). The responses are not usually detected in people with early HIV infection. CD4 T-cell proliferation and response is associated with viremia control in a few long-term non-progressors and in patients whose viremia is controlled by HAART before seroconversion. The researchers divided 159 asymptomatic HIV-1 infected people into different groups receiving triple therapy, double therapy, or no therapy. They measured proliferative response to pokeweed mitogen, recall antigens, tetanus toxoid, a ubiquitous antigen cytomegalovirus, and three HIV-1 recombinant proteins. They found that there was a lack of specific T-cell response to the HIV-1 proteins in all of the individuals and that other responses were similar as well. The authors note that the data indicates, "HAART alone will most likely not be enough to restore HIV-1-specific T-cell helper responses in people with chronic HIV-1 infection," and they suggest that other therapeutic strategies be investigated.